ProCan Clinical
Oncology clinical trials | Targeted | De-risked | Accelerated
A precision medicine laboratory developing protein biomarkers to optimise cancer treatment.
ProCan Technologies can help to de-risk and accelerate your oncology clinical trials by identifying the most appropriate patient population for your therapeutic ie through enabling more targeted clinical trials. This is achieved by looking for unique proteomic biomarkers during early phase clinical trials that are present (before treatment) in patients who respond to the therapy being trialed but absent in non-responders. This biomarker can determine a patient’s likelihood of response and be developed into a patient selection tool for the later, larger clinical trials. It can also be developed as a companion diagnostic for the therapy undergoing trials.
For companies looking to deepen their understanding of the mechanism of action of their therapy, ProCan Technologies can also analyse pre-clinical samples, such as cell lines, organoids, and tumour biopsies.
Patient Selection
ProCan discovers and develops unique biomarkers during early-stage clinical trials that determine a patient’s likelihood of response. This subsequently supports patient selection for late phase clinical trials.
Diagnostics Development
Biomarkers discovered for clinical trials are developed into companion diagnostics.
Prognostic Biomarker Development
ProCan develops powerful protein signatures for many cancer types that help predict likely cancer outcomes and inform treatment options.
Competitive Pricing
Why choose ProCan?
Included Services
Consultation
Consult with ProCan’s team of medical oncologists, data scientists and technology experts who provide customised, affordable solutions for clinical trials.
Sample Preparation
Universal Sample Processing – small sample size, Fresh Frozen (FF), Formalin Fixed Paraffin Embedded (FFPE) tissues, cell lines, patient-derived xenografts, and organoids.
Data Generation
Using state-of-the-art mass spectrometers.
Data Analysis
ProCan bioinformaticians can answer specific questions—interrogating your data alone or providing insights from our powerful database and tens of thousands of clinically annotated cancer specimens.
ProCan de-risks, accelerates and decreases the cost of oncology clinical trials
CASE STUDY
Prognostic signature for pancreatic adenocarcinoma survival
*AACR, 2023. Aref A, Azad AKM et al. Abstract 2209: A proteomic-based prognostic signature of pancreatic adenocarcinoma
Study Design
ProCan retrospectively analysed tissue samples from a cohort of 125 patients with pancreatic adenocarcinoma to identify a prognostic signature for survival.
Identifying the signature
Tissue samples were analysed using ProCan state of-the-art technology to identify tissue proteins. A list of proteins (proteomic signature) was selected using machine learning analyses that could categorise patients into high- and low-risk groups in terms of risk of death from pancreatic cancer.
The proteomic signature is independent of known clinical risk factors
Using the tissue proteins identified in our analyses, ProCan developed a new classification of pancreatic adenocarcinoma, that is independent from clinical and histopathological features. This classification showed
prognostic value in terms of determining risk of death from pancreatic cancer. ProCan identified potential novel therapeutic targets specifically for the poor prognostic group.